These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 19553805)

  • 1. Triple therapy for age-related macular degeneration.
    Augustin A
    Retina; 2009 Jun; 29(6 Suppl):S8-11. PubMed ID: 19553805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single-session photodynamic therapy combined with intravitreal bevacizumab and triamcinolone for neovascular age-related macular degeneration.
    Ahmadieh H; Taei R; Soheilian M; Riazi-Esfahani M; Karkhaneh R; Lashay A; Azarmina M; Dehghan MH; Moradian S
    BMC Ophthalmol; 2007 Jun; 7():10. PubMed ID: 17555600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. One-year follow-up of combined customized therapy. Photodynamic therapy and bevacizumab for exudative age-related macular degeneration.
    Navea A; Mataix J; Desco MC; Garcia-Pous M; Palacios E
    Retina; 2009 Jan; 29(1):13-9. PubMed ID: 18854782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration.
    Goff MJ; Johnson RN; McDonald HR; Ai E; Jumper JM; Fu A
    Retina; 2007; 27(4):432-8. PubMed ID: 17420694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low fluence rate photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration.
    Costagliola C; Romano MR; Rinaldi M; dell'Omo R; Chiosi F; Menzione M; Semeraro F
    Br J Ophthalmol; 2010 Feb; 94(2):180-4. PubMed ID: 19965822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravitreal bevacizumab (Avastin) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age-related macular degeneration: 6-month results of a prospective, randomised, controlled clinical study.
    Weigert G; Michels S; Sacu S; Varga A; Prager F; Geitzenauer W; Schmidt-Erfurth U
    Br J Ophthalmol; 2008 Mar; 92(3):356-60. PubMed ID: 18303156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Approaches toward combining photodynamic therapy with pharmaceuticals that alter vascular microenvironment.
    Busch T
    Retina; 2009 Jun; 29(6 Suppl):S36-8. PubMed ID: 19553798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Re: Verteporfin combination regimens in the treatment of neovascular age-related macular degeneration.
    Nelson M
    Retina; 2010 Feb; 30(2):380; author reply 380-1. PubMed ID: 20142719
    [No Abstract]   [Full Text] [Related]  

  • 9. Intravitreal bevacizumab combined with photodynamic therapy for the treatment of occult choroidal neovascularization associated with serous pigment epithelium detachment in age-related macular degeneration.
    Ladas ID; Kotsolis AI; Papakostas TD; Rouvas AA; Karagiannis DA; Vergados I
    Retina; 2007 Sep; 27(7):891-6. PubMed ID: 17891013
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined treatment modalities for age related macular degeneration.
    Das RA; Romano A; Chiosi F; Menzione M; Rinaldi M
    Curr Drug Targets; 2011 Feb; 12(2):182-9. PubMed ID: 20887244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anatomical benefit from ranibizumab treatment of predominantly classic neovascular age-related macular degeneration in the 2-year anchor study.
    Sadda SR; Stoller G; Boyer DS; Blodi BA; Shapiro H; Ianchulev T
    Retina; 2010 Oct; 30(9):1390-9. PubMed ID: 20924261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Verteporfin combination regimens in the treatment of neovascular age-related macular degeneration.
    Shah GK; Sang DN; Hughes MS
    Retina; 2009 Feb; 29(2):133-48. PubMed ID: 19202423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Visual improvement following intravitreal bevacizumab (Avastin) in exudative age-related macular degeneration.
    Yoganathan P; Deramo VA; Lai JC; Tibrewala RK; Fastenberg DM
    Retina; 2006; 26(9):994-8. PubMed ID: 17151485
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomised trial of bevacizumab and reduced light dose photodynamic therapy in age-related macular degeneration: the VIA study.
    Potter MJ; Claudio CC; Szabo SM
    Br J Ophthalmol; 2010 Feb; 94(2):174-9. PubMed ID: 19520690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravitreal bevacizumab for treatment-naive patients with subfoveal occult choroidal neovascularization secondary to age-related macular degeneration: a 12-month follow-up study.
    Costagliola C; Romano M; Corte MD; Perrotta R; Menzione M; Rinaldi M; Semeraro F; Parmeggiani F
    Retina; 2009 Oct; 29(9):1227-34. PubMed ID: 19934817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Review of combination therapies for neovascular age-related macular degeneration.
    Couch SM; Bakri SJ
    Semin Ophthalmol; 2011 May; 26(3):114-20. PubMed ID: 21609223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiangiogenic therapy in neovascular age-related macular degeneration.
    Lin RC; Rosenfeld PJ
    Int Ophthalmol Clin; 2007; 47(1):117-37. PubMed ID: 17237677
    [No Abstract]   [Full Text] [Related]  

  • 18. Relationships between clinical measures of visual function and anatomic changes associated with bevacizumab treatment for choroidal neovascularization in age-related macular degeneration.
    Unver YB; Yavuz GA; Bekiroğlu N; Presti P; Li W; Sinclair SH
    Eye (Lond); 2009 Feb; 23(2):453-60. PubMed ID: 19039333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of photodynamic therapy alone or combined with posterior subtenon triamcinolone acetonide or intravitreal bevacizumab on choroidal hypofluorescence by indocyanine green angiography.
    Hatta Y; Ishikawa K; Nishihara H; Ozawa S; Ito Y; Terasaki H
    Retina; 2010 Mar; 30(3):495-502. PubMed ID: 19996828
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined ranibizumab and photodynamic therapy to treat exudative age-related macular degeneration: an option for improving treatment efficiency.
    Mataix J; Palacios E; Carmen DM; Garcia-Pous M; Navea A
    Retina; 2010 Sep; 30(8):1190-6. PubMed ID: 20539256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.